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Abstract
In order to eradicate an infecting organism, it is necessary to
achieve or maintain concentrations of an antibiotic in vivo that
exceed the minimum inhibitory concentration (MIC) for the
organism. Duration of exposure, or time above MIC, was
recognized as being important for β-lactam antibiotics more than
60 years ago. Continuous infusion regimens are associated with
higher clinical response rates, improvement in surrogate markers of
outcome, and lower cost of therapy compared with intermittent
infusion regimens, because the MIC can be exceeded for an entire
dosing interval. However, for carbapenem antibiotics, it appears
that the MIC must only be exceeded for 40% of the dosing interval
for bactericidal activity in vivo. Therefore, a promising strategy to
optimize carbapenem use is to administer the same dose at the
same frequency of administration but to extend the infusion time.
Extended infusion regimens take full advantage of a drug’s
exposure potential within the context of in vivo potency without
altering the dose or dosing schedule and with no increase in
toxicity or cost. Administering higher doses by extended infusion
allows one to manage organisms with high MICs. Optimizing the
pharmacokinetics/pharmacodynamics of an antibiotic allows one to
‘make good drugs better’.
Introduction
Utilizing pharmacokinetic/pharmacodynamic principles to
optimize antibiotic administration can improve outcomes. The
in vitro potency of antibiotics is measured as the minimum
inhibitory concentration (MIC). In contrast, the in vivo potency
of an antibiotic refers to its ability to achieve and maintain
concentrations in the body that are necessary to eradicate
infecting organisms. The goal of antibacterial therapy is
generally to maximize in vivo concentrations or the duration of
exposure, depending on the class of antibiotic (Figure 1).
Duration of exposure was recognized as being important for
β-lactam antibiotics more than 60 years ago, when it was
noted that the most effective way to treat an infection with
penicillin was to maintain inhibitory concentrations in the
body throughout treatment [1-3]. Intramuscular injections of
penicillin were recognized as producing high peak concen-
trations that could not be maintained, whereas continuous
intravenous infusions produced constant and sustained
concentrations of penicillin. However, continuous intravenous
infusions of antibiotics fell out of favor as a treatment strategy.
Contributing to the shift in antibiotic administration regimens
were a more plentiful drug supply, the convenience of
intermittent dosing regimens, and a general population of very
susceptible organisms.
Although pharmacokinetic/pharmacodynamic principles have
not changed over the past 60 years, antibiotic administration
strategies are in flux, as the prevalence of resistance increases
and as effective antibiotics become less plentiful, particularly
for Gram-negative organisms. For β-lactams, old philosophies
are being revisited to increase the duration of the dosing
interval that antibiotic concentrations exceed the MIC. The
various methods to achieve this goal include administering
doses more frequently and administering higher doses.
However, dose escalation strategies usually are not cost-
effective. Administering two times the dose neither doubles
the time above the MIC nor optimizes exposure to the
antibiotic, but it does increase the cost of therapy (Figure 2).
Infusion strategies
Continuous infusion
During the 1940s, bacterial endocarditis was effectively
treated with penicillin administered as a continuous infusion
[4]. There is a resurgence of interest in using a continuous
infusion of an antibiotic dose administered via pump over
24 hours after a loading dose. The goal of continuous
infusion therapy is to maintain drug concentrations above the
MIC for the entire 24-hour interval by selecting the
appropriate dose. Several studies have demonstrated that
continuous infusion of β-lactam antibiotics is an effective
dosing strategy.
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The efficacies of administering carbenicillin plus tobramycin
by continuous infusion, carbenicillin plus cefamandole by
continuous infusion, and carbenicillin plus cefamandole by
intermittent infusion were compared in a randomized study of
490 febrile episodes (235 documented infections) in neutro-
penic cancer patients [5]. Carbenicillin was administered
over 2 hours every 4 hours, whereas tobramycin was adminis-
tered as a loading dose followed by continuous infusion, and
cefamandole was administered either as a continuous
infusion after a loading dose or as an intermittent infusion
every 6 hours. Overall, the carbenicillin plus cefamandole
regimens were more effective than carbenicillin plus
tobramycin, with cure rates of 65% for the carbenicillin plus
cefamandole continuous infusion, 57% for the carbenicillin
plus cefamandole intermittent infusion, and 54% for carbeni-
cillin plus tobramycin. In profoundly neutropenic patients
(initial neutrophil count <100/mm3 and no increase during
the infection), the continuous infusion cefamandole regimen
was three times more effective than the intermittent regimen
(65% versus 21%; P = 0.03). Although these agents are no
longer drugs of choice for treating these infections, the study
does support the pharmacokinetic/pharmacodynamic princi-
ple of maintaining drug concentration above the MIC through-
out the dosing interval to improve efficacy.
Contemporary studies provide additional support for this
pharmacokinetic/pharmacodynamic principle as a rationale
for designing antibiotic regimens. An open-label study com-
pared continuous versus intermittent administration of pipera-
cillin plus tazobactam in 98 patients at a large community
teaching hospital [2]. It found that clinical (94% versus 82%)
and microbiologic (89% versus 73%) success rates were
slightly higher with the continuous infusion regimen, although
the difference was not statistically significant. The continuous
infusion regimen, however, was associated with a significantly
shorter time to temperature normalization (1.2 ± 0.8 days
versus 2.4 ± 1.5 days; P = 0.012) and a trend toward faster
normalization of the white blood cell count (2.8 ± 2.4 days
versus 3.9 ± 2.2 days; P = 0.065). In addition, the drug
acquisition cost per patient was less with the continuous
infusion regimen ($291 ± 218 versus $371 ± 325; P= 0.054),
and all costs associated with antibiotic use were significantly
lower with the continuous infusion regimen ($399 ± 407
versus $523 ± 526; P = 0.028).
The results of a randomized, multicenter, open-label study com-
paring continuous infusion piperacillin/tazobactam (12 g/1.5 g
administered continuously over 24 hours) with the standard
intermittent infusion (3 g/0.375 g administered over 30 minutes
intermittently every 6 hours) in patients with complicated
intra-abdominal infections were recently reported [6]. Patient
demographics were similar among groups, as was the
percentage of those clinically cured or improved (86.4% of
those treated with continuous infusion versus 88.4% for
intermittent infusion; P = 0.817). Bacteriologic success was
not statistically different between the two treatment groups
(P = 0.597). Moreover, drug-related adverse events were
similar, despite the differing administration techniques utilized.
Additional studies conducted at our institute [7,8] have also
illustrated the clinical and microbiologic attributes of con-
tinuous infusion regimens in the management of both
community-acquired and nosocomial pneumonia.
A recently published trial [9] reported on the clinical utility of
a β-lactam administered by continuous infusion. In this trial, a
lower daily dose (2 g) of cefotaxime given by continuous
infusion to patients with chronic obstructive pulmonary
Figure 1
In vivo potency as a pharmacodynamic parameter for antibiotic
therapy. Maintaining antibiotic concentrations above the minimum
inhibitory concentration (MIC) is necessary to achieve in vivo potency
and is dependent on the pharmacokinetics of the drug. AUC, area
under the concentration-time curve; Cmax, maximum plasma
concentration; T>MIC, time spent above the MIC.
Figure 2
Dose escalation as a strategy to improve antibiotic efficacy. Dose
escalation either by administering higher doses or administering a
dose more frequently achieves only small increments in efficacy
because there is little increase in the time during which the drug
concentration is above the minimum inhibitory concentration (MIC).Page 3 of 5
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disease produced clinical and microbiological effects similar
to those with a higher total daily dose of 1 g administered
three times daily. Moreover, the continuous infusion regimen
resulted in pharmacodynamic (time above MIC) optimization
of cefotaxime therapy. These data further suggest that
continuous infusion yields similar clinical outcomes in a cost-
effective manner - an observation that has been noted in
other studies utilizing this therapeutic approach [2,8].
Studies also have demonstrated the efficacy of carbapenem
antibiotics administered by continuous infusion in critically ill
patients and in patients with resistant pathogens. In a small,
prospective, crossover study conducted in critically ill
patients [10], pharmacokinetic parameters for meropenem
differed significantly between intermittent and continuous
infusion. Although the area under the concentration-time
curve was significantly lower after continuous infusion, the
mean steady state concentration was above the MIC for
common bacterial strains for the entire infusion interval. A
retrospective study of patients with ventilator-associated
pneumonia [11] found that the clinical cure rate was
significantly higher after continuous infusion of meropenem
than after intermittent infusion (90.5% versus 59.6%;
P < 0.001). Because meropenem is stable for only 4 to
6 hours at room temperature, the drug supply was changed
every 6 hours to achieve a continuous infusion. In a
randomized, open-label study conducted in seven adults with
cystic fibrosis [12] the investigators evaluated administration
of meropenem (3 g/24 hours or 6 g/24 hours) over 12 hours
by a continuous ambulatory drug-delivery infusion pump
stored in a cold pouch between two freezer packs. Drug
stability was maintained over 12 and 24 hours, and the
pharmacokinetic parameters were dose dependent, with
mean steady-state drug concentrations of 8.3 μg/ml and
18.5 μg/ml for the 3 g and 6 g doses at 12 hours. These
serum concentrations were twofold to fourfold greater than
the MICs of organisms considered susceptible (MIC ≤4 μg/ml)
or intermediately resistant (MIC of 8 μg/ml) to meropenem.
Continuous infusion regimens have therefore been associa-
ted with enhanced clinical response rates, improvement in
surrogate markers of outcome, and a lower cost of therapy
compared with intermittent infusion regimens. Various
strategies may be used successfully to overcome drug
stability issues.
Extended infusion
Continuous infusion of β-lactam antibiotics has the potential
to maintain drug concentrations above the MIC over a
24-hour interval. However, it is not necessary to exceed the
MIC for an entire dosing interval. For carbapenem antibiotics
the required time above the MIC appears to be 20% of the
dosing interval for bacteriostatic and 40% of the dosing
interval for bactericidal activity in vivo [13-16]. Another
strategy to optimize antibiotic use is to administer the same
dose at the same frequency of administration but to extend
the infusion time. This strategy overcomes the limited stability
of carbapenem antibiotics at room temperature and increases
the time above the MIC. Simulations predict that extended
infusions can achieve maximal kill rates for organisms with
high MICs [15,17].
Pharmacokinetic/pharmacodynamic studies provide a
rationale for extended infusion regimens. An extended
infusion of carbapenem has a pharmacokinetic profile similar
to that of a 0.5-hour infusion of the same dose, but it
improves the pharmacodynamic profile (time above MIC;
Figure 3) [18]. In a crossover study conducted to assess the
pharmacodynamic profile of meropenem in healthy volunteers
[18], the time above MIC (at the susceptibility breakpoint of
4 μg/ml) could be increased from 30% to 43% for the 0.5 g
dose and from 58% to 73% for the 2 g dose when the
infusion was extended from 0.5 to 3 hours. Surveillance data
show that meropenem MICs are 4 μg/ml or less for most
isolates of Pseudomonas aeruginosa [19,20]. Although the
time above MIC for more resistant strains (such as those with
MICs of 8 or 16 μg/ml) is considerably reduced when con-
ventional doses and/or administration techniques are used,
drug concentrations can be maintained above these elevated
MICs by both increasing the dose and using an extended
infusion. This of course requires use of a carbapenem that
can be safely dosed at these levels without fear of central
nervous system toxicity. A patient-based simulation for the
carbapenems demonstrated that utilization of extended
infusions increased the probability of achieving bactericidal
exposures for multidrug-resistant P. aeruginosa (Table 1) [17].
Moreover, the utilization of higher doses of meropenem
administered as extended infusions further increased the
probability of achieving bactericidal exposures for this
resistant population of organisms. These data suggest that
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Figure 3
Benefits of extended infusion. An extended infusion time for a
carbapenem increases the time the drug concentration is above the
minimum inhibitory concentration (MIC) compared with a shorter
infusion time and overcomes the instability of carbapenems at room
temperature [18].resistant organisms may successfully be treated by optimizing
dosing regimens based on pharmacokinetic/pharmaco-
dynamic parameters.
The extended infusion dosing strategy has resulted in good
outcomes in the clinical setting [21,22]. Sufficient antibiotic
doses administered as an extended infusion with the same
frequency as recommended for shorter infusions (for example,
meropenem 2 g administered over 3 hours every 8 hours) not
only maintained serum concentrations but also prolonged
exposure at the site of infection (for example, lung) [21,23].
At one institution, a patient-based simulation of piperacillin-
tazobactam exposures versus the anticipated MIC profile was
used to identify a dosing regimen of this compound that
would optimize its pharmacodynamic profile (>50% of a
dosing interval spent above MIC) [22]. An institution-wide
automatic substitution program was implemented based on
the simulation results (piperacillin-tazobactam 3.375 g
infused over 4 hours every 8 hours replaced piperacillin-
tazobactam 3.375 g infused over 30 minutes every 4 or
6 hours), and outcomes for the two regimens were compared
in a retrospective cohort study of critically ill patients with
infections caused by P. aeruginosa. In patients at greatest
mortality risk (Acute Physiology and Chronic Health
Evaluation II score ≥17), the extended infusion regimen
significantly reduced 14-day mortality compared with the
intermittent infusion regimen (12.2% versus 31.6%;
P = 0.04) as well as median length of stay (21 days versus
38 days; P = 0.02). In addition to improved clinical outcomes,
the extended infusion regimen, which represents a 25% to
50% reduction in total daily piperacillin-tazobactam dose,
resulted in an annual reduction in drug acquisition costs of
$68,750 to $135,750.
An additional factor to consider in selecting extended or
continuous infusion is that the total costs of intravenous
antibiotic administration are not just the costs of the drugs
themselves but also comprise costs resulting from the time
expended by medical and nursing staff, costs of disposable
materials, and overhead costs. These nonacquisition costs of
antibiotic administration should be taken into account.
Infusion with syringe pumps and volumetric pumps has been
shown to be the most cost-effective strategy for adminis-
tering antibiotics [24].
Extended infusion regimens therefore take full advantage of a
drug’s exposure potential within the context of in vivo
potency without altering the dose or dosing schedule and
with no increase in toxicity. Administering higher doses allows
one to treat patients with severe illness and/or organisms
with high MICs. Importantly, extended infusion regimens are a
cost-effective strategy.
Conclusion
Optimizing the pharmacokinetics/pharmacodynamics of an
antibiotic allows one to ‘make good drugs better’. Extended
infusion regimens improve the effectiveness of therapy with
few limitations and provide a cost-effective strategy.
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